MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genprex, Inc. - Common Stock (NQ:GNPX)

0.5343 +0.0153 (+2.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genprex, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Dow Flat as Tesla Lifts Tech, Autos ↗
The Dow Jones Industrial Average is flat midday, as it cools off from this morning's burst higher. Both the S&P 500 Index and Nasdaq Composite are more comfortably in the black. 
Via Talk Markets
News headline image
GNPX Stock: 5 Things to Know as Genprex Rockets Higher ↗
Shares of GNPX stock are soaring higher after the FDA granted fast track designation (FTD) for the company's lead drug candidate, REQORSA. 
Via InvestorPlace
News headline image
8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE ↗
We're diving into the top penny stocks to watch today as several names in the space see major movement on Monday alongside heavy trading. 
Via InvestorPlace
News headline image
Why Genprex Shares Are Soaring Today ↗
Genprex Inc (NASDAQ: GNPX) is trading higher Monday after the company announced it received U.S. Food and Drug Administration Fast Track Designation (FTD) for REQORSA... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted Fast Track Designation for Proprietary Immunogene Therapy from FDA
Via Investor Brand Network
News headline image
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting ↗
The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Immix Biopharma (NASDAQ:IMMX) shares increased by 61.5% to $5.75 during Monday's pre-market session. The company's market cap stands at $43.5 million.... 
Via Benzinga
News headline image
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present in CEO Roadshow Webinar
Via Investor Brand Network
News headline image
Genprex to Present in November CEO Roadshow Webinar
From Genprex, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Tenet Healthcare (NYSE:THC) stock r... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Strengthens Management Team with Strategic Appointments
Via Investor Brand Network
News headline image
Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Two Upcoming Investor Conferences
Via Investor Brand Network
News headline image
Genprex to Participate in September Investor Conferences
From Genprex, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers MorphoSys (NASDAQ:MOR) stock move... 
Via Benzinga
News headline image
Genprex to Participate in a Monthly CEO Roadshow Webinar Series
From Genprex, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Orphazyme (NASDAQ:ORPH) shares moved upwards by 32.66% to $7.92 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of... 
Via Benzinga
News headline image
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
From Genprex, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers AnPac Bio-Medical Science (NASDAQ:ANPC) stock rose 21.47% to $5.26 during Friday's pre-market session. The company's market cap stands at $68.5 million.... 
Via Benzinga
News headline image
Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
From Genprex, Inc.
Via Business Wire
News headline image
Genprex to Participate in Upcoming May Investor Conferences
From Genprex, Inc.
Via Business Wire
News headline image
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer
From Genprex, Inc.
Via Business Wire
News headline image
Diamond Equity Research Emerging Growth Invitational Spring 2021 Virtual Conference
- One Day Conference May 11, 2021 - 25 Minute Presenting Time Slots From 8:30am to 1:25pm EST - Presentation Times and Links Distributed for All Presenting Companies - Investors Will Be Provided Time... 
From Diamond Equity Research LLC
Via AccessWire
News headline image
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
News headline image
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
News headline image
Genprex to Participate in CEO Roadshow Webinar Series
From Genprex, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story